Endologix (ELGX) : During the past 4 weeks, traders have been relatively bearish on Endologix (ELGX), hence the stock is down -17.28% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.05% relative to the S&P 500. The 4-week change in the price of the stock is -16.43% and the stock has fallen -6% in the past 1 week.
The stock has recorded a 20-day Moving Average of 12.66% and the 50-Day Moving Average is 11.05%. Endologix (NASDAQ:ELGX): On Fridays trading session , Opening price of the stock was $11.78 with an intraday high of $11.87. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $11.59. However, the stock managed to close at $11.6, a loss of 1.28% for the day. On the previous day, the stock had closed at $11.75. The total traded volume of the day was 692,876 shares.
The company Insiders own 3.9% of Endologix shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -9.95% . During last six month period, the net percent change held by insiders has seen a change of -9.95%. Also, Brokerage firm RBC Capital downgrades its rating on Endologix (NASDAQ:ELGX). The shares have been rated Sector Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on August 3, 2016.
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.